Activities of p53 promoters isolated from p53-null myeloid cells. Promoter sequences were cloned on to luciferase reporter vectors and transfected into U2OS and T98G cells. p1p and HHF represent promoters cloned from cells that express p53. Results are derived from triplicate experiments and are expressed as relative light units. expression of p53 in human myeloid cells is not due to defects in cisacting regulatory elements of the gene.
with simultaneous occurrence of CTLGLP with CBLPD and discuss possible pathogenetic mechanisms underlying such associations. Case histories were as follows (see also Tables 1 and 2 Case 2, a 54-year-old female, with long-standing steroid-unresponsive idiopathic thrombocytopenic purpura who had undergone splen- ). PCR analysis identified clonally rearranged TCRgamma and immunoglobulin heavy chain (IgH) genes in the PB and BM, respectively. Two-and-a-half years later, the patient has neither major clinical problems nor significant changes in hematology values. The evidence presented herein suggests that in our series T-LGL leukemia grew concomitantly with CBLPDs. Documentation of the clonal T-LGL and B cell entities was based upon morphologic criteria (apart from case No. 8 in whom PB lymphocytes lacked typical LGL morphology; however, occasionally, clonally expanded lymphocytes with a characteristic CD3 + CD57 + phenotype may not have LGL morphology on PB smear 1 ), immunophenotypic analysis and genotypic profile. Their distribution in the tissues examined was immunophenotypically and genotypically discriminate.
The low frequency both of the CBLPDs identified in our cases and T-LGL leukemia suggests that their simultaneous occurrence might not be fortuitous. The possibility that the CTLGLPs detected in our patients might react to the monoclonal B cell populations is not very likely: this is supported by the findings in case No. 8, where the spleen and liver were massively infiltrated by neoplastic T-LGLs. Furthermore, it can not be definitely excluded that the CBLPDs identified might share a common malignant precursor with T-LGL leukemias. Another, in our view more plausible, explanation might be that CBLPDs emerged secondarily due to B cell dysfunction in the setting of T-LGL leukemia; 1, 5, 6 in most cases, unlike LGLs from healthy individuals, abnormally expanded T-LGL leukemia cells, despite being CD8 + , are incapable of suppressing immunoglobulin synthesis in vivo. 1 Thus, uncontrolled Ig production with autoantibody formation could eventually lead to the development of clonal B cell disorders, as in the few cases in the literature and in our cases as well. 1, 3, 4 However, it should not be overlooked that T-LGLs with cytotoxic/suppressor phenotype might function as contrasuppressor T cells.
In conclusion, our cases support the notion that T-LGL leukemia can coexist with B cell dysfunction and/or B cell lymphoproliferative diseases, including MGUS and multiple myeloma; the exact pathophysiologic mechanism awaits further clarification. Furthermore, these results emphasize the value of a combined immunophenotypic and molecular analysis of the PB as part of the evaluation of CBLPDs in order to detect CTLGLP, which may pass unnoticed on morphologic examination. Finally, it is not unreasonable to argue that while investigating limited BM SLIs the hemopathologist should be alert for the possibility of coexisting B and T lymphoproliferations.
